Do Ophthalmic Solutions of Amphotericin B Solubilised in 2-Hydroxypropyl-γ-Cyclodextrins Possess an Extended Physicochemical Stability?
amphotericin B
fungal keratitis
stability
γ-cyclodextrins
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
19 Aug 2020
19 Aug 2020
Historique:
received:
15
07
2020
revised:
06
08
2020
accepted:
17
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
Fungal keratitis is a sight-threatening disease for which amphotericin B eye drops is one of the front-line treatments. Unfortunately, there are currently no commercial forms available, and there is little data concerning the long-term stability of compounded formulations based on intravenous dosages forms. New formulations of amphotericin B ophthalmic solutions solubilised with γ-cyclodextrins have shown promising in-vitro results, but stability data is also lacking. The objective of this study was therefore to investigate the stability of a formulation of ready-to-use amphotericin B solubilised in 2-hydroxypropyl-γ-cyclodextrins (AB-HP-γ-CD), for 350 days. An amphotericin B deoxycholate (ABDC) formulation was used as a comparator. Analyses used were the following: visual inspection, turbidity, osmolality and pH measurements, amphotericin B quantification by a stability-indicating liquid chromatography method, breakdown product research, and sterility assay. AB-HP-γ-CD formulation showed signs of chemical instability (loss of amphotericin B) after 28 and 56 days at 25 °C and 5 °C. Adding an antioxidant (ascorbic acid) to the formulation did not improve stability. ABDC formulation showed signs of physical instability (increased turbidy and amphotericin B precipitation) after 28 days and 168 days at 25 °C and 5 °C. As such, AB-HP-γ-CD formulation does not provide long-term stability for ophthalmic amphotericin B solutions.
Identifiants
pubmed: 32825121
pii: pharmaceutics12090786
doi: 10.3390/pharmaceutics12090786
pmc: PMC7559369
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Klin Monbl Augenheilkd. 2019 Apr;236(4):358-365
pubmed: 30616287
J Mycol Med. 2014 Dec;24(4):e137-42
pubmed: 25442914
Int J Ophthalmol. 2016 Nov 18;9(11):1676-1683
pubmed: 27990375
J Pharm Pharmacol. 1973 May;25(5):401-7
pubmed: 4146396
Langmuir. 2007 Aug 14;23(17):8718-25
pubmed: 17637009
J Ocul Pharmacol Ther. 2019 Jan/Feb;35(1):6-22
pubmed: 30481082
J Fr Ophtalmol. 2017 Nov;40(9):e307-e313
pubmed: 28987448
Ann Clin Microbiol Antimicrob. 2020 Mar 30;19(1):11
pubmed: 32228660
Antimicrob Agents Chemother. 1990 Feb;34(2):183-8
pubmed: 2183713
J Pharm Biomed Anal. 2007 Sep 21;45(1):70-81
pubmed: 17646076
Am J Ophthalmol. 2018 Nov;195:161-170
pubmed: 30098351
Adv Clin Exp Med. 2015 Nov-Dec;24(6):1113-7
pubmed: 26771986
J Ophthalmic Vis Res. 2020 Apr 06;15(2):128-137
pubmed: 32308946
J Fungi (Basel). 2017 Oct 18;3(4):
pubmed: 29371573
Eur J Pharm Sci. 2017 Mar 30;100:230-237
pubmed: 28131754
Int J Pharm. 2014 Oct 1;473(1-2):148-57
pubmed: 24998510
Pharmazie. 2017 Dec 1;72(12):741-746
pubmed: 29441959
Int J Antimicrob Agents. 2018 Mar;51(3):326-332
pubmed: 28705676
J Infect Public Health. 2019 May - Jun;12(3):367-371
pubmed: 30600158
FEBS Lett. 2000 Jan 7;465(1):83-6
pubmed: 10620711
Int J Pharm. 2012 Nov 1;437(1-2):80-2
pubmed: 22890190
Biomed Res Int. 2019 Jan 20;2019:6395840
pubmed: 30800674
Clin Exp Ophthalmol. 2007 Jul;35(5):421-6
pubmed: 17651246
Int J Pharm. 2007 Nov 1;344(1-2):150-3
pubmed: 17669608
J Antibiot (Tokyo). 1985 Dec;38(12):1822-4
pubmed: 4093341
Front Cell Infect Microbiol. 2020 Apr 03;10:133
pubmed: 32318355
J Pharm Sci. 2010 Feb;99(2):719-29
pubmed: 19670293
J Pharm Biomed Anal. 2004 Nov 15;36(3):579-86
pubmed: 15522533
Surv Ophthalmol. 2019 May - Jun;64(3):380-400
pubmed: 30797882
Antimicrob Agents Chemother. 1997 Apr;41(4):743-7
pubmed: 9087481
J Antibiot (Tokyo). 2011 Nov;64(11):735-9
pubmed: 21971300
Biopolymers. 1989 Sep;28(9):1585-96
pubmed: 2775849
J Pharm Biomed Anal. 2007 Sep 21;45(1):82-96
pubmed: 17716847
Mycoses. 2018 Dec;61(12):916-930
pubmed: 29992633
Clin Exp Ophthalmol. 2019 Jan;47(1):26-32
pubmed: 29931733
J Infect Public Health. 2020 Aug;13(8):1089-1093
pubmed: 32580917
J Pharm Sci. 1993 Feb;82(2):162-6
pubmed: 8383201
J Phys Chem A. 2015 Jan 15;119(2):369-76
pubmed: 25514626
Pharmaceutics. 2020 Apr 20;12(4):
pubmed: 32326044
Int J Pharm Compd. 1999 Jul-Aug;3(4):316-20
pubmed: 23985715